Brown, Lisle/Cummings’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.88M Buy
66,985
+148
+0.2% +$3.94K 0.47% 52
2025
Q4
$1.66M Buy
66,837
+2,301
+4% +$58K 0.41% 59
2025
Q3
$1.64M Sell
64,536
-5,070
-7% -$125K 0.42% 57
2025
Q2
$1.69M Buy
69,606
+7,101
+11% +$166K 0.45% 55
2025
Q1
$1.58M Buy
62,505
+1,197
+2% +$31.3K 0.46% 54
2024
Q4
$1.63M Buy
61,308
+3,824
+7% +$104K 0.49% 54
2024
Q3
$1.66M Buy
57,484
+158
+0.3% +$4.61K 0.51% 51
2024
Q2
$1.6M Buy
57,326
+2,263
+4% +$62.3K 0.52% 48
2024
Q1
$1.53M Buy
55,063
+4,843
+10% +$134K 0.52% 47
2023
Q4
$1.45M Buy
50,220
+15,990
+47% +$483K 0.54% 47
2023
Q3
$1.14M Buy
34,230
+7,927
+30% +$280K 0.51% 49
2023
Q2
$965K Buy
26,303
+4,879
+23% +$190K 0.43% 57
2023
Q1
$874K Buy
21,424
+1,457
+7% +$62.9K 0.44% 54
2022
Q4
$1.02M Buy
19,967
+1,749
+10% +$83.9K 0.55% 48
2022
Q3
$797K Buy
18,218
+2,730
+18% +$133K 0.47% 53
2022
Q2
$812K Sell
15,488
-432
-3% -$22K 0.45% 58
2022
Q1
$824K Sell
15,920
-432
-3% -$22.4K 0.4% 62
2021
Q4
$966K Buy
+16,352
New +$810K 0.48% 52

Other funds holding PFE

Brown, Lisle/Cummings's PFE Position: Q1 2026 in Review

Brown, Lisle/Cummings increased its Pfizer (PFE) stake by 0.22% in Q1 2026, buying an estimated $3.94K and bringing the position to 66,985 shares worth $1.88M. The position accounts for 0.47% of the portfolio, ranked #52.

Brown, Lisle/Cummings first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Brown, Lisle/Cummings held 66,985 shares of Pfizer worth $1.88M as of Q1 2026.
  • Brown, Lisle/Cummings bought 148 Pfizer shares in Q1 2026, an estimated $3.94K.
  • Pfizer made up 0.47% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #52 holding.
  • Brown, Lisle/Cummings first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.